New York State Common Retirement Fund boosted its holdings in Grifols SA, Barcelona (NASDAQ:GRFS) by 3.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,133,205 shares of the biotechnology company’s stock after buying an additional 37,157 shares during the quarter. New York State Common Retirement Fund owned approximately 0.17% of Grifols SA, Barcelona worth $24,806,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in GRFS. Ameriprise Financial Inc. boosted its stake in Grifols SA, Barcelona by 14,219.5% in the second quarter. Ameriprise Financial Inc. now owns 1,901,199 shares of the biotechnology company’s stock valued at $40,153,000 after buying an additional 1,887,922 shares in the last quarter. Westpac Banking Corp acquired a new stake in Grifols SA, Barcelona in the third quarter valued at about $9,767,000. JPMorgan Chase & Co. boosted its stake in Grifols SA, Barcelona by 13.1% in the second quarter. JPMorgan Chase & Co. now owns 2,178,611 shares of the biotechnology company’s stock valued at $46,035,000 after buying an additional 252,169 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. boosted its stake in Grifols SA, Barcelona by 795.2% in the third quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 263,175 shares of the biotechnology company’s stock valued at $5,761,000 after buying an additional 233,775 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Grifols SA, Barcelona in the second quarter valued at about $4,860,000. 22.52% of the stock is currently owned by institutional investors and hedge funds.
GRFS has been the topic of several research analyst reports. Citigroup initiated coverage on Grifols SA, Barcelona in a research note on Tuesday, October 31st. They issued a “buy” rating on the stock. UBS lowered Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Zacks Investment Research lowered Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BidaskClub lowered Grifols SA, Barcelona from a “sell” rating to a “strong sell” rating in a research note on Saturday. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. Grifols SA, Barcelona currently has a consensus rating of “Hold” and a consensus price target of $24.00.
Shares of Grifols SA, Barcelona (NASDAQ GRFS) opened at $21.57 on Tuesday. Grifols SA, Barcelona has a 12 month low of $14.52 and a 12 month high of $24.20. The company has a market capitalization of $5,730.00, a PE ratio of 20.28, a PEG ratio of 1.64 and a beta of 1.02. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17.
COPYRIGHT VIOLATION NOTICE: “New York State Common Retirement Fund Has $24.81 Million Stake in Grifols SA, Barcelona (GRFS)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/12/new-york-state-common-retirement-fund-has-24-81-million-stake-in-grifols-sa-barcelona-grfs.html.
Grifols SA, Barcelona Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.